JP2009280511A - 皮膚外用かゆみ止め剤 - Google Patents
皮膚外用かゆみ止め剤 Download PDFInfo
- Publication number
- JP2009280511A JP2009280511A JP2008132410A JP2008132410A JP2009280511A JP 2009280511 A JP2009280511 A JP 2009280511A JP 2008132410 A JP2008132410 A JP 2008132410A JP 2008132410 A JP2008132410 A JP 2008132410A JP 2009280511 A JP2009280511 A JP 2009280511A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- agent
- lower alcohol
- water
- external
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003908 antipruritic agent Substances 0.000 title abstract description 6
- 208000003251 Pruritus Diseases 0.000 claims abstract description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004202 carbamide Substances 0.000 claims abstract description 19
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 18
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 17
- 230000001387 anti-histamine Effects 0.000 claims description 17
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 11
- 229960004194 lidocaine Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000004909 Moisturizer Substances 0.000 claims description 4
- 229960000520 diphenhydramine Drugs 0.000 claims description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 abstract description 17
- 230000037336 dry skin Effects 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 210000003491 skin Anatomy 0.000 description 39
- 235000019441 ethanol Nutrition 0.000 description 34
- 230000007803 itching Effects 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 7
- 239000003906 humectant Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 150000005690 diesters Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940045136 urea Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 101710200374 Crotamine Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- PEFQQQGFYPMQLH-WFQFKEFWSA-N crotamin Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CC=4NC=NC=4)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=4C=CC(O)=CC=4)CSSC[C@@H](C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=2C4=CC=CC=C4NC=2)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=CC=C1 PEFQQQGFYPMQLH-WFQFKEFWSA-N 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- -1 diphenhydramine Chemical class 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】低級アルコール及び水を含む溶媒中に、尿素、抗ヒスタミン剤及び局所麻酔剤を溶解乃至分散させてなる皮膚外用かゆみ止め剤であって、低級アルコール:水(重量比)=1:0.6〜1.3であり、低級アルコールと水の合計量が、該かゆみ止め剤全体を基準として、60〜90w/v %であることを特徴とする皮膚外用かゆみ止め剤。
【選択図】図1
Description
2. 尿素を5〜20w/v %、抗ヒスタミン剤を0.5〜5w/v %。局所麻酔剤を0.5〜5w/v %含有する上記項1に記載の皮膚外用かゆみ止め剤。
3. 下記組成範囲の各成分を含有することを特徴とする上記項1又は2に記載の皮膚外用かゆみ止め剤。
尿素 5〜20w/v%
抗ヒスタミン剤 0.5〜 5w/v%
局所麻酔剤 0.5〜 5w/v%
低級アルコール 30 〜50w/v%
精製水 25〜40w/v%
保湿剤 1〜10w/v%
4. 抗ヒスタミン剤がジフェンヒドラミン又はその薬理的に許容される塩であり、局所麻酔剤がリドカインであり、低級アルコールがエタノールである上記項1〜3のいずれかに記載の皮膚外用かゆみ止め剤。
抗ヒスタミン剤 0.5〜 5w/v%
局所麻酔剤 0.5〜 5w/v%
低級アルコール 30 〜50w/v%
精製水 25〜40w/v%
保湿剤 1〜10w/v%
表1に示す配合組成(w/v %)のかゆみ止め剤を下記の方法によって調製した。
公知の皮膚外用剤として下記表2に示す配合組成(w/v %)の液剤を実施例1に準じた方法で調製した。これを比較試料1とする。
(1)試験試料
実施例1で得た本発明かゆみ止め剤及び比較例1で得たかゆみ止め剤(比較試料1)を用いて、下記の方法でマウスによるかゆみ抑制効果の試験を行った。更に、実施例1で得た本発明かゆみ止め剤からジフェンヒドラミン塩酸塩を除いた液剤(比較試料2)、実施例1で得た本発明かゆみ止め剤からリドカインを除いた液剤(比較試料3)、及び実施例1で得た本発明かゆみ止め剤から尿素、ジフェンヒドラミン塩酸塩及びリドカインを除いた液剤(比較試料4)の各液剤を用いた場合と、かゆみ止め剤を無塗布の場合についても同様の試験を行った。
NAOマウスに各試験試料を塗布し、30分後にかゆみ惹起剤であるヒスタミン遊離剤(Compound 48/80)を皮下投与し、投与5分後〜35分後の30分間におけるマウスのかゆみ掻破行動を観察し、その時間を計測した(N=5)。結果を図1に示す。
図1から明らかなように、本発明かゆみ止め剤によれば、公知の皮膚外用剤である比較試料1と比較して高いかゆみ抑制効果が認められた。
図2に概略図を示すフランツ拡散セルを用いて、下記の方法によって、本発明かゆみ止め剤と、公知の皮膚外用液剤である比較試料1について、シリコン膜によるリドカインの吸収性試験を行った。
本発明かゆみ止め剤と、公知の皮膚外用剤である比較試料1について、下記の方法で保湿効果の試験を行った。
Claims (4)
- 低級アルコール及び水を含む溶媒中に、尿素、抗ヒスタミン剤及び局所麻酔剤を溶解乃至分散させてなる皮膚外用かゆみ止め剤であって、低級アルコール:水(重量比)=1:0.6〜1.3であり、低級アルコールと水の合計量が、該かゆみ止め剤全体を基準として、60〜90w/v %であることを特徴とする皮膚外用かゆみ止め剤。
- 尿素を5〜20w/v %、抗ヒスタミン剤を0.5〜5w/v %。局所麻酔剤を0.5〜5w/v %含有する請求項1に記載の皮膚外用かゆみ止め剤。
- 下記組成範囲の各成分を含有することを特徴とする請求項1又は2に記載の皮膚外用かゆみ止め剤。
尿素 5〜20w/v%
抗ヒスタミン剤 0.5〜 5w/v%
局所麻酔剤 0.5〜 5w/v%
低級アルコール 30 〜50w/v%
精製水 25〜40w/v%
保湿剤 1〜10w/v% - 抗ヒスタミン剤がジフェンヒドラミン又はその薬理的に許容される塩であり、局所麻酔剤がリドカインであり、低級アルコールがエタノールである請求項1〜3のいずれかに記載の皮膚外用かゆみ止め剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008132410A JP5761678B2 (ja) | 2008-05-20 | 2008-05-20 | 皮膚外用かゆみ止め剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008132410A JP5761678B2 (ja) | 2008-05-20 | 2008-05-20 | 皮膚外用かゆみ止め剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009280511A true JP2009280511A (ja) | 2009-12-03 |
JP5761678B2 JP5761678B2 (ja) | 2015-08-12 |
Family
ID=41451372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008132410A Active JP5761678B2 (ja) | 2008-05-20 | 2008-05-20 | 皮膚外用かゆみ止め剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5761678B2 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03291221A (ja) * | 1989-07-27 | 1991-12-20 | Otsuka Pharmaceut Factory Inc | 皮膚外用液剤 |
JP2001163777A (ja) * | 1999-09-30 | 2001-06-19 | Toyama Chem Co Ltd | 皮膚外用液剤 |
JP2007262030A (ja) * | 2006-03-29 | 2007-10-11 | Kobayashi Pharmaceut Co Ltd | 皮膚外用剤 |
-
2008
- 2008-05-20 JP JP2008132410A patent/JP5761678B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03291221A (ja) * | 1989-07-27 | 1991-12-20 | Otsuka Pharmaceut Factory Inc | 皮膚外用液剤 |
JP2001163777A (ja) * | 1999-09-30 | 2001-06-19 | Toyama Chem Co Ltd | 皮膚外用液剤 |
JP2007262030A (ja) * | 2006-03-29 | 2007-10-11 | Kobayashi Pharmaceut Co Ltd | 皮膚外用剤 |
Also Published As
Publication number | Publication date |
---|---|
JP5761678B2 (ja) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5619337B2 (ja) | 皮膚残渣を最小限に抑えるための経皮的医薬製剤 | |
JP3487633B2 (ja) | 皮膚疾患治療乳剤 | |
JP2009519940A (ja) | 皮膚科学的状態を処置するための組成物および方法 | |
JP2009519958A (ja) | 薬物の皮膚送達のための、フラックス化可能な組成物および方法 | |
JP2003528821A (ja) | 局所適用のための薬学的および化粧用の担体または組成物 | |
JP2000319187A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP4549006B2 (ja) | ゲル軟膏 | |
JP2009184951A (ja) | 皮膚外用剤組成物 | |
JP5052558B2 (ja) | ゲル軟膏 | |
TW201912156A (zh) | 組成物在製備治療睡眠障礙的藥劑的用途 | |
TW200403077A (en) | Trans-dermal absorption preparation | |
JP2011088930A (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP5643872B2 (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP2003095985A (ja) | 血行促進組成物 | |
JP2019142856A (ja) | ロキソプロフェン配合皮膚用外用剤 | |
JPH03291221A (ja) | 皮膚外用液剤 | |
JP5170973B2 (ja) | 皮膚外用剤 | |
JP2012092067A (ja) | 非ステロイド性消炎鎮痛外用剤 | |
JP5164438B2 (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP5699184B2 (ja) | 二酸化炭素経皮・経粘膜吸収用組成物 | |
JP4450545B2 (ja) | エアゾール製剤 | |
JP5761678B2 (ja) | 皮膚外用かゆみ止め剤 | |
US8367683B2 (en) | Composition and method for treatment of warts | |
JP2018203674A (ja) | 皮脂分泌促進剤及び外用組成物 | |
JP3723728B2 (ja) | 皮膚外用液剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130520 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150602 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5761678 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |